Skip to main content
. 2016 Sep 8;11(9):e0162316. doi: 10.1371/journal.pone.0162316

Fig 2. Changes in levels of IL-6, sTNF-R1 and sTNF-R2 following 6 months of treatment with adalimumab or infliximab.

Fig 2

Level of IL-6 and sTNF-R1 and sTNF-R2 were determined in 26 patients with rheumatoid arthritis, 15 patients treated with adalimumab, and 11 patients treated with infliximab. Levels were determined prior to treatment (Baseline) and following 6 months of treatment (Follow-up). Levels of IL-6 (A) and sTNF-R2 (C) decreased significantly during treatment. *p < 0.05. Medians and interquartile ranges are shown.